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Abstract
Background Treating breast cancer patients with everolimus and exemestane can be challenging due to toxicity and suboptimal
treatment responses.
Objective We investigated whether everolimus exposure and early metabolic response are predictors for toxicity and effective-
ness in these patients.
Patients and Methods We performed pharmacokinetic assessments 14 and 35 days after starting treatment.
[18F]fluorodeoxyglucose-positron emission tomography (18F-FDG-PET) was performed at baseline, and 14 and 35 days after
the start of the therapy. We recorded toxicity, defined as dose interventions within 3 months, and progression-free survival (PFS).
Results Among 44 evaluable patients, the geometric mean (GM) Ctrough was higher in patients with toxicity compared to patients
without (17.4 versus 12.3 μg/L (p = 0.02)). The optimal cut-off value to predict toxicity was Ctrough > 19.2 μg/L. GM Ctrough of
patients with and without progressive disease (PD) within 3 months was not significantly different (12.0 versus 15.2 μg/L (p =
0.118)). In 28 evaluable patients, PD within 3 months could best be predicted using the percentage decrease in peak standardized
uptake value normalized by lean body mass of the lesion with highest FDG uptake (SULpeak high) at day 14. Patients with <11%
versus >11% decrease in SULpeak high at day 14 had a median PFS of 90 days versus 411 days, respectively (p = 0.0013) and more
frequently had PD within 3 months: 70 vs 11%, respectively.
Conclusions Our results show that everolimus toxicity is related to everolimus Ctrough. No relation was observed between
everolimus exposure and treatment effectiveness. An early FDG-PET can identify patients at high risk of nonresponse. These
results warrant further validation. Clinicaltrials.gov identifier: NCT01948960.
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1 Introduction
The introduction of the combination treatment of everoli-
mus and exemestane markedly improved clinical outcomes
in patients with hormone receptor positive metastatic
breast cancer (mBC) [1]. Since the BOLERO-2 study,
several trials have subsequently confirmed the beneficial
effect on treatment outcomes in these patients [2–4].
Unfortunately, not all patients benefit from this treatment.
In the BOLERO-2 study, 10% of patients had progressive
disease (PD) as best overall response and the clinical ben-
efit rate (stable disease, partial response, and complete
response) for ≥24 weeks was only 51% [5].
Importantly, patients treated with this regimen can experi-
ence severe everolimus-induced side effects, as 27% of pa-
tients experience grade 3 or 4 toxicity [6]. Moreover, low
grade toxicities have a significant impact on the quality of life
of these patients as well and can necessitate dose adjustments.
Therefore, treating breast cancer patients with everolimus can
be challenging. Early prediction of toxicity and nonresponse
would greatly facilitate clinical decision-making. Everolimus
exposure, patient characteristics, and early metabolic response
could be predictors for toxicity and response and may be used
as pharmacokinetic and pharmacodynamic biomarkers.
Currently, these biomarkers are not used in routine clinical
practice.
Everolimus for mBC patients is prescribed at a fixed dose,
but shows substantial interindividual variation in drug expo-
sure of 36–45% [7–10]. Evidence is mounting that the evero-
limus trough concentration (Ctrough) is an important predictive
factor for toxicity and effectiveness [11–14]. The largest study
so far, with 938 patients with solid tumors, showed that a
twofold increase in everolimus Ctrough increased the likelihood
of tumor size reduction by approximately 40% [12]. In pa-
tients with mBC, metastatic renal cell carcinoma (mRCC),
or neuro-endocrine tumors, an everolimus Ctrough >
11.9 μg/L was associated with a threefold increase in progres-
sion free survival (PFS) and a Ctrough < 26.3 μg/L was associ-
ated with a fourfold decreased risk of toxicity [11].
Patient characteristics can be relevant, as subgroups such as
obese or elderly patients can show different pharmacokinetics
compared to other patients. Obesity can lead to an increased
volume of distribution, increased hepatic blood flow, higher
CYP3A4 activity, and a change in plasma binding [15, 16].
Everolimus pharmacokinetics in elderly patients can differ as
a result of decreased absorption due to gastric atrophy, lower
first pass effect due to a decrease in hepatic blood flow, and
reduced CYP3A4 activity [17–20]. The net result of all these
influences on drug disposition in obese or elderly patients is
yet unknown.
Functional imaging to assess metabolic response could
serve as an early biomarker for the evaluation of response to
treatment. The inhibition of activity of oncogenic proteins by
everolimus and exemestane can result in rapid metabolic
changes. These metabolic changes can be detected using
[18F]fluorodeoxyglucose-positron emission tomography
(FDG-PET). Early detection of nonresponse to treatment can
facilitate early decisionmaking, including dose adjustments or
a change of therapy. Preclinical data suggest that FDG-PET is
a suitable imaging modality for response assessment to evero-
limus treatment [21–25]. A clinical study of FDG-PETchang-
es inmRCC patients treated with everolimus showed amodest
correlation between metabolic changes and change in tumor
size [26]. In mBC patients on endocrine therapy or chemo-
therapy, metabolic response on FDG-PETwas a good predic-
tor of PFS [27, 28]. For mBC patients treated with everolimus
and exemestane, to the best of our knowledge, no clinical
study assessing the predictive value of FDG-PET for treat-
ment response has yet been published.
The current study aimed to investigate whether everolimus
exposure is related to the development of toxicity and treat-
ment effectiveness in patients with mBC. We hypothesized
that a therapeutic window for everolimus can be established,
in which the balance between toxicity and effectiveness is
optimal. Additionally, we explored whether early FDG-PET
evaluation can be used as an early read-out for effectiveness.
In this way, an ineffective therapy could be stopped earlier,
preventing unnecessary toxicity and costs.
2 Materials and Methods
2.1 Patients and Study Design
The present study was an explorative, prospective, open-label,
comparative study carried out in six hospitals in the
Netherlands. We included women planning to start treatment
with exemestane and everolimus. Patients using medication
recognized as being strong inhibitors or inducers of CYP3A
isoenzymes were excluded and no such medication was
allowed during the study.
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Key Points
In breast cancer patients treated with everolimus and 
exemestane, everolimus  Ctrough is an important predictor 
of toxicity, as patients with Ctrough >19.2 µg/L have a 
higher risk of clinically relevant toxicity.
A lack of decrease in metabolic activity measured by 
FDG-PET/CT after 14 days of treatment can identify a 
subgroup of patients at high risk of nonresponse, for 
whom an early adjustment of therapy or extra follow-up 
could be considered.
Patients could participate either in the pharmacokinetic part
of the study or in the combined pharmacokinetic and imaging
part. For the pharmacokinetic part, patients were enrolled in
three subgroups: control (<70 years and body mass index
(BMI) <30 kg/m2), obese (<70 years and BMI ≥30 kg/m2),
and elderly (≥70 years and BMI <30 kg/m2). Planned enroll-
ment was 25 patients per subgroup, but due to slow recruit-
ment the study closed earlier. For the combined pharmacoki-
netic and imaging part, 40 patients were planned for inclusion.
In the imaging part of the study, patients who were elderly and
obese could also be included. The study protocol was ap-
proved by the Radboudumc Ethics Committee (reference
number 2013–284) and registered as clinicaltrials.gov
identifier: NCT01948960. All patients gave written informed
consent. The study was performed in accordance with the
Declaration of Helsinki.
2.2 Clinical Evaluation
We recorded baseline characteristics, including previous treat-
ments. Clinical evaluation took place before the start of ther-
apy, and after 14, 35, 60, and 90 days of treatment. Response
assessment was performed with CT of chest and abdomen at
baseline, and subsequently every three months. On the physi-
cian’s discretion, additional investigations, such as bone scin-
tigraphy, could be performed. Follow-up took place until pro-
gressive disease (PD) (even if everolimus or exemestane were
discontinued earlier) and the reason for treatment discontinu-
ation was recorded. PFS was defined as the time from start of
treatment until PD or death. PD was assessed using Response
Evaluation Criteria in Solid Tumors (RECIST) 1.1 [29]. If
RECIST assessment was not possible, PD was assessed by
other imaging techniques, CA 15.3 marker, or was clinically
determined. If patients had PD within 14 days after stopping
everolimus treatment, patients were scored as PD on treat-
ment. Patients were censored for PFS and time to dose change
event at time of everolimus discontinuation.
We recorded adverse events using Common Terminology
Criteria for Adverse Events 4.0.We considered adverse events
leading to a dose change clinically most relevant. Therefore,
we defined toxicity as adverse events requiring a dose change
within 3 months after start of treatment. All dose changes were
recorded until discontinuation of treatment. In our analysis,
we included all dose reductions or dose discontinuations that
were a result of toxicity at least probably related to everoli-
mus. Temporary drug interruptions without dose changes
were not included.
2.3 Pharmacokinetic Analysis and Intervention
We performed everolimus pharmacokinetic assessment after
14 days of treatment. In the imaging part, a second pharma-
cokinetic assessment was performed at day 35. In the case of
dose interruptions, treatment had to be restarted at least 7 days
prior to pharmacokinetic assessment to ensure steady state
pharmacokinetics. Blood samples were collected before
(Ctrough) and 1, 2, 3, 5, and 8 h after administration of evero-
limus. The trough sample was extrapolated as a 24 h sample.
The area under the concentration time curve (AUC0-24h) was
calculated using a noncompartmental trapezoidal approach
(Phoenix WinNonlin v6.3®). We measured everolimus con-
centrations in whole blood by a validated liquid chromatogra-
phy tandem mass spectrometry technique.
Patients in the imaging part who had a low everolimus
AUC0-24h (<550 μg*h/L) at day 14 were randomized 2:1 to
have a dose escalation or not [7, 8]. Dose escalation was cal-
culated to achieve an AUC >550 μg*h/L. Patients in whom
the dose was escalated were excluded for the analysis of the
relationship between Ctrough and toxicity and effectiveness.
2.4 FDG-PET Acquisition and Analysis
In the imaging part of the study, patients underwent FDG-PET
at baseline, and after 14 and 35 days of treatment. Activity was
analyzed using standardized uptake values normalized by lean
body weight (SUL), using the Janmahasatian formula [30].
We performed analysis by PERCIST criteria [31]. We mea-
sured SULpeak (mean SUL in a volume of interest (VOI) of
1 cm3) and SULmax (voxel with highest activity). For five
target lesions we determined the sum of the SULmax
(sumSULmax) and the sum of the SULpeak (sumSULpeak),
and the SULpeak of the lesion with the highest uptake
(SULpeak high). For total lesion glycolysis (TLG), a tumor
VOI was determined with a threshold of minimally two times
mean activity of selected reference tissue. TLG then was de-
fined as the mean uptake times the volume of this VOI, and
the sum for up to five lesions was determined (sumTLG).
Additionally, a qualitative judgment was performed indepen-
dently by two nuclear medicine physicians.
Further details can be found in the SupplementaryMaterial.
2.5 Statistical Analyses
Before statistical tests were performed, Ctrough data were log
(base 10) transformed, in order to obtain more symmetrically
distributed data. A two sample t-test based on the transformed
data was used to test for differences in the mean Ctrough be-
tween patients with and without toxicity and response. To test
for differences in the mean of the transformed Ctrough between
the three subgroups (control, obese, elderly), a one-way
ANOVA was used, followed by post-hoc analysis (equality
of variances was tested with Bartlett’s test). No Bonferroni
adjustment was performed for this post-hoc analysis, as this
is an explorative study.
For the analyses described below, the untransformed
Ctrough data were used. The association between Ctrough and
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age and BMI were analyzed, first visually and next with a
multivariable linear regression model with Ctrough as depen-
dent variable and age and BMI as independent variables. For
the association of Ctrough with toxicity and effectiveness, re-
ceiver operating characteristic (ROC) curve analysis was per-
formed and the AUC was determined. Optimal cut-off values
were determined using the Youden index, the value associated
with the highest sum of sensitivity + specificity – 1. The cor-
relation between Ctrough and metabolic change on FDG-PET
was estimated with Spearman’s correlation.
PFS and the time to dose change were estimated by the
Kaplan-Meier estimator. A log rank test was performed to test
whether the survival curves were significantly different. Two
separate multivariable Cox proportional hazards regression
models were fitted for PFS and the time to dose change, using
backward selection based on a likelihood ratio test with
p > .10 for removal. Age and BMI were used as covariates
for the analysis of time to a dose change event. The ROC
analysis was used to assess which variable of everolimus ex-
posure and which variable of metabolic change had the stron-
gest association with PD within 3 months. These variables
were then used as covariates in the multivariable model for
the analysis of time to PFS. Model assumptions, including
proportional hazards and linearity, were checked and if needed
the model was adjusted. Furthermore, the number of previous
treatments was added in this model as a covariate, as this
generally is a significant predictor of PFS.
Analyses were performed with SPSS v22 and graphs were
created using GraphPad Prism v5.03.
3 Results
3.1 Study Subjects
Between October 2013 and October 2017, we enrolled 61
subjects. Four patients dropped out due to screen failure and
from two patients we could not obtain pharmacokinetic data.
The remaining 55 patients were subdivided into 34 control
patients, ten obese patients, nine elderly patients, and two
patients that were elderly and obese. Baseline characteristics
of these patients are presented in Table 1. Twenty patients had
an AUC0-24h < 550 μg*h/L, and 14 patients were randomized
to have dose escalation. In three patients dose escalation was
not executed, as everolimus treatment had already been
interrupted or discontinued. Therefore, 44 patients were suit-
able for analysis of the relationship between everolimus
Ctrough and toxicity; 43 patients were evaluable for the rela-
tionship between everolimus Ctrough and effectiveness, as one
patient had used exemestane pretreatment, which was not
allowed in the study. In four out of these 43 patients, PD
was established based on imaging or clinical aspects, as
RECIST assessment was not possible. In the imaging part of
the study, 39 patients were included. Of these, 29 patients had
lesions with sufficient FDG avidity at baseline and were eli-
gible to proceed for metabolic response monitoring using
FDG-PET. From one of these 29 patients no FDG-PET was
performed at day 14.
3.2 General Pharmacokinetics of Everolimus
In the 55 patients, the geometric mean (GM) Ctrough was
12.6 μg/L (range 4.6–37.5 μg/L) and AUC0-24h was
565 μg*h/L (range 261–1162 μg*h/L). Ctrough was a good
predictor of AUC0-24h, with coefficient of determination
(r2) = 0.84 (p < 0.001). Nineteen patients had everolimus con-
centrations measured at 2 and 5 weeks, without a concurrent
dose change. In these patients, the intra-individual coefficient
of variation for everolimus at day 14 and day 35 was low:
16.8% for Ctrough and 14.8% for AUC0-24h.
3.3 Main Outcomes
3.3.1 Relationship of Ctrough and Toxicity
The reason for everolimus discontinuation was PD in 70% of
patients, versus 30% due to toxicity. A dose change due to
toxicity within 3 months occurred in 45% of patients. The
median time to the first dose changewas 52 days (9–159 days).
Of 24 patients with a dose change event, this occurred in the
first 14 days of treatment in only two patients. No dose chang-
es occurred after day 159 of treatment. The most frequent
reason for a dose change or interruption was stomatitis and
the most frequent reason for discontinuation was pulmonary
toxicity. Patients with a dose change <3 months had a signif-
icantly higher GMCtrough compared to patients without a dose
change <3 months: 17.4 μg/L and 12.3 μg/L, respectively
(p = 0.02). ROC analysis to predict dose change using
Ctrough showed an AUC of 0.71 (p = 0.02). Ctrough was a
slightly better predictor of toxicity than AUC0-24h, with an
AUC of 0.66. Optimal cut-off value was Ctrough > 19.2 μg/L,
with sensitivity 55% and specificity 92%. Thirteen out of 44
patients (30%) had a Ctrough above this threshold. Eleven out
of these 13 patients (85%) had toxicity leading to a dose
change <3 months, compared to nine out of 31 (29%) patients
who did not develop toxicity, resulting in a relative risk of 2.9.
Median time to first dose adjustment was significantly shorter
for patients with Ctrough > 19.2μg/L compared to patients with
Ctrough < 19.2 μg/L, 42 days versus not reached, p = 0.0008
(Fig. 1), hazard ratio (HR) 5.8 (95% CI 2.1–16.1). When a
cut-off of 26.3 μg/L was used, as proposed previously [11],
median time to first dose adjustment for patients with
Ctrough > 26.3 μg/L was 47 days, compared to not reached
for patients with Ctrough < 26.3 μg/L, p = 0.0028.
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3.3.2 Relationship of Ctrough and Effectiveness
GM everolimus Ctrough of patients with and without PD
<3 months was 12.0 μg/L and 15.2 μg/L, respectively (p =
0.118). ROC analysis to predict PD <3 months using Ctrough
showed an AUC = 0.64, p = 0.15. Ctrough was a slightly better
predictor of effectiveness than AUC0-24h with an AUC of
0.60. The optimal cut-off value for Ctrough was <12.6 μg/L,
with sensitivity 69% and specificity 60%. Twenty-one out of
43 patients (48%) had an everolimus Ctrough below this thresh-
old. Nine of these 21 patients (43%) had PD <3 months, com-
pared to four out of 23 (17%) patients with everolimus
Ctrough > 12.6 μg/L, resulting in a relative risk of 2.5. No rel-
evant difference was seen in the frequency of censoring in the
Kaplan-Meier survival analysis, as four out of 21 patients
were censored in the group patients with Ctrough < 12.6 μg/L,
and six out of 22 in the group patients with Ctrough >
12.6 μg/L. Median PFS time was not significantly different
for patients with Ctrough > 12.6 μg/L and < 12.6 μg/L: 318
versus 153 days respectively (p = 0.19), HR 0.85 (95% CI
0.41–1.77) (Fig. 2).
The relationship between Ctrough and PFS was different for
the period of the first 365 days of treatment and after this
period, as shown in a Cox regression analysis with time-
dependent Ctrough, dichotomized for above or below
12.6 μg/L.
The outcomes of the effect of weight (obese) and age
(elderly) on everolimus pharmacokinetics are presented in
the Electronic supplementary material.
3.4 Exploratory Outcomes: Response assessment
Using FDG-PET
Of all performed PET scans, 70 met the acquisition criteria as
set by PERCIST. Lesions had sufficient FDG uptake in 20 of
22 patients (91%) with ductal carcinoma, compared to eight of
12 patients (67%) with lobular carcinoma.
ROC analysis showed that of sumSULmax, sumSULpeak,
SULpeak high, and sumTLG at day 14 and day 35, the percent-
age decrease in SULpeak high at day 14 (SULpeak high d14) was
the best predictor of PD <3months. A cut-off of 11% decrease
in SULpeak high d14 was optimal (Fig. 3), with an AUC of 0.78,
sensitivity 0.78, and specificity 0.84. Patients with PD
<3 months had a significantly lower mean decrease in
SULpeak high d14 compared to patients without PD <3 months:
7.1% versus 23.0% (p = 0.02). Median PFS was 90 days for
patients with <11% decrease in SULpeak high d14, compared to
388 days for patients with >11% decrease, p = 0.0013 (Fig. 4).
Seven out of ten patients (70%) with <11% decrease in
SULpeak high d14 had PD <3 months, compared to two out of
18 patients (11%) with a decrease >11%, resulting in a relative
risk of 6.4.
Fig. 1 Inverse Kaplan-Meier estimates of time to dose change event,
based on differences in exposure
Table 1 Baseline patient








Age (years), mean (SD) 61.6 (9.7) 58.1 (8.6) 59.5 (6.5) 74.2 (2.9)
BMI (kg/m2), mean (SD) 26.2 (4.4) 24.4 (3.0) 32.8 (3.0) 24.6 (1.9)
Number of previous treatment lines, mean (min-max)
In adjuvant setting 1.0 (0–4) 0.8 (0–4) 1.9 (0–3) 0.8 (0–3)
In metastatic setting 2.1 (0–6) 1.9 (0–6) 1.8 (0–3) 3.1 (2–6)
Total 3.2 (1–6) 2.8 (1–6) 3.7 (3–6) 3.9 (2–6)
Histology (%)
Ductal carcinoma 71 71 45 89
Lobular carcinoma 26 23 55 11
Fig. 2 Kaplan-Meier estimates of progression-free survival, based on
differences in exposure
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When using the European Organisation for Research and
Treatment of Cancer (EORTC) response criteria of > versus
<15% decrease in uptake in SULpeak high d14, median PFS
was 440 versus 110 days (p = 0.0039). Using the PERCIST
response criteria of > versus <30% decrease and ≥ 0.8 SUL
units in SULpeak high d14, median PFS was 440 versus
137 days (p = 0.115).
Using the qualitative assessment according to EORTC
criteria, PERCIST criteria, and the consensus reading of two
nuclear medicine physicians, the accuracy to predict RECIST
classification after three months of treatment was poor, with
0.24, 0.34, and 0.39, respectively. The negative predictive
value of a partial metabolic response to predict the absence
of progressive disease at three months according to EORTC
criteria, PERCIST criteria, and the physician consensus read-
ing was 0.78, 0.88, and 0.70, respectively.
No significant correlation was found between everolimus
Ctrough and the decrease in SULpeak high d14 (Spearman’s rho =
−0.31, p = 0.108). Dose escalation did not result in a stronger
decrease in metabolic activity between day 14 and 35 com-
pared to no dose escalation (n = 8 vs. n = 17).
3.5 Multivariable Analysis to Predict PFS
The total number of previous lines of treatments in the adju-
vant and metastatic settings was a significant predictor of PFS.
Median PFS time was 341 days for patients with 1 to 3 pre-
vious treatments (n = 38) and 90 days for patients with 4 to 6
previous treatments (n = 19) (p = 0.003), HR 0.32 (95% CI
0.15–0.86). Multivariable Cox regression analysis to estimate
time to PFS event was performed using dichotomized Ctrough
at day 14, SULpeak high d14, and the number of previous treat-
ments as covariates. Based on the plots of the Kaplan-Meier
curves (Fig. 2), the HR for the dichotomized variable Ctrough in
the Cox proportional hazards model was allowed to be differ-
ent before and after one year after diagnosis. From these co-
variates, SULpeak high d14 and the number of previous treat-
ments were significantly associated with PFS (Table 2).
4 Discussion
The present study shows that patients with high everolimus
trough concentrations (>19.2 μg/L) have a higher chance of
clinically relevant toxicity leading to dose changes. It is clin-
ically highly relevant to know that one third of patients are
exposed to high everolimus Ctrough, with a nearly threefold
increased risk to develop toxicity, as this toxicity can poten-
tially be prevented by dose adjustments.
The upper limit for toxicity that we found is comparable with
the results of a recent, independently performed study [11]. As
such, we were able to validate the importance of Ctrough as a
predictor of toxicity. If early dose reduction in the group of pa-
tients with Ctrough > 19.2μg/L can reduce the dose change risk to
the risk of patients with Ctrough < 19.2μg/L, severe toxicity could
potentially be prevented in ~50% of these patients.
Secondly, we show that, as early as 14 days after start of
treatment, FDG-PET can identify a subgroup of patients with a
high risk of nonresponse to everolimus and exemestane. To our
knowledge, this is the first prospective evaluation of the value of
FDG-PET to predict outcomes of treatment with everolimus and
exemestane in mBC patients. A decrease in SULpeak high d14 of
<11%was found to be the best predictor for early PD, but the cut-
off as proposed by EORTC (≥15% decrease) was a significant
predictor as well. The cut-off used in the PERCISTclassification
(≥30% decrease) in this study was not a significant predictor.
Perhaps the criterion of PERCIST is too stringent for response
monitoring of agents that inhibit the activity of oncogenic pro-
teins. If a patient has a poor decline in metabolic activity on
FDG-PETat day 14, the treating physician can consider to adjust
therapy or to follow this patient extra cautiously. This can aid to
give patients optimal outcomes from their anticancer therapy and
to avoid side effects and costs of an ineffective treatment.
Additionally, lobular carcinomas more frequently had lesions
Fig. 4 Kaplan-Meier estimates of progression free survival, based on
differences in metabolic /response at day 14
Fig. 3 Decrease in SULpeak high d14 for patients with and without
progressive disease within 3 months. Each bar represents one patient
Table 2 Cox proportional hazards model for time to PFS event
HR 95% CI P value
Ctrough at day 14 > or < 12.6 μg/L
a 0.999 0.904–1.103 0.978
SULpeak high d14 0.960 0.932–0.990 0.087
Number of previous treatments 1.352 0.957–1.910 0.009
a, Ctrough < 12.6 μg/L served as the reference group
SUL, standardized uptake values normalized by lean body weight
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with low FDG activity, consistent with earlier experiences [32],
but the majority of lobular carcinomas were suitable for FDG-
PET response monitoring.
In our data, Ctrough was no significant predictor of effec-
tiveness. The relatively small sample size of our study in-
creases the chance that we were not able to demonstrate a
difference between these groups. A previous study did show
a significant relationship between Ctrough and effectiveness
[11]. Another study showed no correlation between dose in-
tensity and response rate or PFS, but no everolimus concen-
trations were measured in that study [33]. The weak relation-
ship between everolimus Ctrough and outcomes can be ex-
plained by the presence of exemestane-sensitive tumors that
would also have responded without adding everolimus to the
treatment. This also can explain the crossing of the PFS sur-
vival curves that was seen in our data (Fig. 2). Unfortunately,
up to now it cannot be predicted which tumors are
exemestane-sensitive and do not need the combination with
everolimus treatment. The fact that no relationship was seen
between everolimus Ctrough and metabolic response supports
the notion that other factors influence the effectiveness of
everolimus and exemestane besides everolimus Ctrough.
An additional finding of this study, described in the sup-
plementary file, was that no significant effect of elderly age
and obesity was established on everolimus Ctrough. However,
due to the small sample size there was limited power to detect
a possible difference, and no firm conclusions can be drawn.
Elderly patients more frequently had dose changes due to
toxicity compared to control patients. This is in contrast with
a previous study in which everolimus dosemodifications were
not seen more frequently in patients of ≥70 years (n = 118)
compared to patients <70 years (n = 364) [34].
Furthermore, we have shown that Ctrough is a better predic-
tor for toxicity and effectiveness compared to a full AUC with
eight measurements. The importance of Ctrough compared to
AUC was also demonstrated in a recent preclinical study
showing that continuous low dosing above a certain threshold
can be as effective as intermittent dosing with a higher AUC
[35]. It has substantial practical benefits if the collection of
only one blood sample is sufficient and even superior.
The strong points of our study are the prospective nature of
our study with the collection of extensive pharmacokinetic
data. Our pharmacokinetic results are in agreement with the
findings of several other studies.
Our study also has limitations. Firstly, the sample size of our
study is relatively small. Hence, this is an exploratory, hypothesis
generating, study. Furthermore, the value of FDG-PET as an
early read-out is limited by the fact that very few patients are
classified as PD after three months. As such, it was not possible
to identify individuals with 100% chance on early progression.
To advance the care for patients with mBC, we need to
further individualize treatment in order to improve effective-
ness and reduce toxicity. The most important finding to
emerge from this study is that monitoring everolimus Ctrough
has the potential to identify patients at high risk of developing
toxicity. For the future, a patient should have everolimus
Ctrough determined seven days after start of treatment, so that
toxicity potentially can be prevented through early dose ad-
justments. A prospective evaluation to study whether thera-
peutic drug monitoring to reach everolimus drug concentra-
tions in a target window leads to better patient outcomes is
currently ongoing (M17 TDM study). Furthermore, after start
of treatment a poor decrease in metabolic activity at day 14 on
FDG-PET seems to be an important signal of possible ineffec-
tive treatment, but these results require further validation.
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